AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Half-Life: Alyx is a 2020 virtual reality (VR) first-person shooter game developed and published by Valve. It was released for Windows on March 23, 2020, and for Linux on May 15, with support for most PC-compatible VR headsets. Players control Alyx Vance on a mission to seize a superweapon belonging to the alien Combine before the events of Half-Life 2 (2004). Like previous Half-Life games, Alyx incorporates combat, puzzles and exploration. Players use VR to interact with the environment and fight enemies, using "gravity gloves" to snatch objects from a distance, similarly to the gravity gun from Half-Life 2. The previous Half-Life game, Episode Two, was released in 2007 and ended on a cliffhanger. Valve made several attempts to develop further Half-Life games, but could not settle on a direction. In the mid-2010s, Valve began experimenting with VR and identified demand for a major VR game. They experimented with prototypes using their various game series, such as Portal, and found that Half-Life best suited VR. Alyx entered production using Valve's new Source 2 engine in 2016, with the largest team in Valve's history, including members of Campo Santo, a studio acquired by Valve in 2018. VR affected almost every aspect of the design, including level design, combat, movement and pacing. Valve planned to launch Alyx alongside its Index headset in 2019, but delayed it to rewrite the story following internal feedback. Alyx received acclaim for its graphics, voice acting, narrative and atmosphere, and has been described as the first VR killer app.
Affinity towards An(III) over Ln(III) Good An(III) back-extraction to enable solvent recycling Good solubility in a proper diluent CHON compliance to reduce secondary waste Fast complexation kinetics Hydrodynamic stability to prevent third phase and precipitates formation during extraction process Chemical and radiolytic stability to prevent solvent degradation Research on advanced reprocessing of spent nuclear fuel moves on by developing process optimization studies and designing new potential lipophilic and hydrophilic extracting agents that fulfill these industrial requirements.
In early July 2018, then Education Minister, Lisa Thompson, told Queen's Park reporters that starting in September 2018, Ontario schools would no longer be using the sex education curriculum in use since 2015, but would be reverting to the previous curriculum. One of the election campaign promises by the Ford government was to "scrap" the 2015 sex education curriculum. Premier Ford's government said that "it did not order the cancellation." By August 2019, the Ministry of Education, following "widespread consultations," made "only minor tweaks". The "health lesson plan being brought to schools in the fall" of 2019 "is similar to the one Ford crusaded against." On October 11, 2019, Minister Lecce reached a deal with CUPE school support workers, which has to be ratified by CUPE members and averted a pending strike. Premier Ford had said that he would cap "all public sector wage settlements at one per cent per year". The three-year agreement with CUPE was for a "one per cent wage increase annually for the duration of deal." A clause in the agreement clause in the agreement says that if "higher increases are negotiated by other education unions", their union will be able to increase to more than one percent. CUPE also had $58.3 million restored for the "hiring of educational assistants" with an additional $20 million for hiring "more custodians and clerical workers." As well, CUPE's sick leave provisions remained untouched.
==== Hair bleaching and coloring ==== Diluted H2O2 (between 1.9% and 12%) mixed into a solution with aqueous ammonia, aniline (color molecule) and a coupler, has been used to color human hair. It can also be mixed with powder or cream bleach compounds, most notably potassium chloride. Bleaching hair follicles does not destroy or remove color molecule or melanocytes. Bleaching compounds work to drive wedges between color molecules or melanocytes, allowing more visible light to pass through the hair shaft. The chemical's bleaching property lends its name to the phrase "peroxide blonde". Hydrogen peroxide is also used for tooth whitening. It may be found in most whitening toothpastes. Hydrogen peroxide has shown positive results involving teeth lightness and chroma shade parameters. It works by oxidizing colored pigments onto the enamel where the shade of the tooth may become lighter. Hydrogen peroxide may be mixed with baking soda and salt to make a homemade toothpaste.
Sources: en.wikipedia.org
Shaun Slater, a Bromley councillor who tweeted that it was "more likely" a rape victim was a prostitute whose "punter... didn't pay", is expelled from the Conservative Party. 16 April – Around 600 Amazon workers based in Coventry and belonging to the GMB trade union begin a three-day strike over pay. 17 April – Prime Minister Rishi Sunak announces a review of the "core maths content" taught in England's schools, with the establishment of a panel to conduct the review. 24 April – The publishers of Big Issue North announce it is to cease publication in May, citing rising costs and reduced footfall in town centres. 25 April – South West Water implements a hosepipe ban for large parts of Devon in an attempt to replenish water levels at the Roadford Reservoir ahead of the summer. 26 April – West Midlands Police launch a murder inquiry after a man is stabbed near Queensbridge School in Kings Heath. The next day 2 People are arrested. The Royal College of Midwives announces that its members have voted to accept the government's pay offer for NHS workers in England. 28 April – Members of the Unite union, mostly ambulance workers and junior healthcare staff, reject the UK government's 5% pay offer for NHS workers in England. The offer is rejected by around half of the 55% who voted. The 5% NHS England pay offer is backed by the GMB union. Four teaching unions in England – the National Education Union, NASUWT, National Association of Head Teachers and the Association of School and College Leaders – announce plans to co-ordinate strike action.
=== Macrocyclic CSPs === An interesting way of achieving chiral distinction on a CSP is the use of selectors with chiral cavity. These chiral selectors are attached to the stationary phase support material. In this category, there are basically three types of cavity chiral selectors namely cyclodextrins, crown ethers and macrocyclic glycopeptide antibiotics. Among these cyclodextrin based CSP is popular. In this type of CSPs the enantioselective guest-host interaction governs the chiral distinction.
Choosing a software tool for structural alignment can be a challenge due to the large variety of available packages that differ significantly in methodology and reliability. A partial solution to this problem was presented in and made publicly accessible through the ProCKSI webserver. A more complete list of currently available and freely distributed structural alignment software can be found in structural alignment software. Properties of some structural alignment servers and software packages are summarized and tested with examples at Structural Alignment Tools in Proteopedia.Org.
== Refining the techniques == The next development was gas chromatography (GC). Martin and Synge had predicted its principles in their 1941 paper. Erika Cremer laid the theoretical basis of GC in 1944. Austrian chemist Fritz Prior, under the direction of Erika Cremer, constructed in 1947 the first prototype of a gas chromatograph and achieved separating oxygen and carbon dioxide, in 1947 during his Ph.D. research. Beginning in 1949, Martin and Anthony T. James worked on developing GC. At his 1952 Nobel lecture, Martin announced the successful separation of a wide variety of natural compounds by GC. GC was quickly adopted since it is easy and efficient for separating organic chemicals, and new detection methods for analyzing the output were quickly developed. The thermal conductivity detector, described in 1954 by N. H. Ray, was the foundation for several other methods: the flame ionization detector by J. Harley, W. Nel, and V. Pretorius in 1958, and the electron capture detector by James Lovelock in 1958. Others introduced mass spectrometers to gas chromatography in the late 1950s. The work of Martin and Synge also set the stage for high performance liquid chromatography (HPLC), suggesting that small sorbent particles and pressure could produce fast liquid chromatography techniques. This became widely practical by the late 1960s (and the method was used to separate amino acids as early as 1960).
== Reception and publication == Fleming's discovery was initially regarded as unimportant. Even as he showed his culture plates to his colleagues, all he received was an indifferent response. He described the discovery on 13 February 1929 before the Medical Research Club. His presentation, titled "A medium for the isolation of Pfeiffer's bacillus", did not receive any particular attention. In 1929, Fleming reported his findings to the British Journal of Experimental Pathology on 10 May 1929, and published them in the next month's issue. His article failed to attract any serious attention. Fleming himself was quite unsure of the medical application of his work and was more concerned with its application for bacterial isolation, as he concluded:
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.